Guggenheim Issues Pessimistic Forecast for Sensei Biotherapeutics (NASDAQ:FTH) Stock Price

Key Points

• Guggenheim lowered its Sensei Biotherapeutics price target from $70 to $69 but maintained a Buy rating; the new target implies about 254% upside from the cited share price of $19.51.
• Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus and an average price target of $56.17, with 15 of 17 analysts rating it Buy or Strong Buy.
• Sensei reported a quarterly loss of $0.79 per share, missing analysts’ estimate of a $0.66 loss; shares traded at $19.51, below their 50-day average of $28.24.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) had its target price dropped by stock analysts at Guggenheim from $70.00 to $69.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a "buy" rating on the stock. Guggenheim's price objective would suggest a potential upside of 253.59% from the company's current price.

FTH has been the subject of several other research reports. Needham & Company LLC assumed coverage on Sensei Biotherapeutics in a research note on Friday, August 21st. They issued a "buy" rating and a $56.00 target price for the company. William Blair started coverage on shares of Sensei Biotherapeutics in a report on Friday, October 16th. They issued an "outperform" rating on the stock. HC Wainwright restated a "buy" rating and issued a $60.00 price objective on shares of Sensei Biotherapeutics in a research report on Tuesday, August 11th. JonesTrading initiated coverage on shares of Sensei Biotherapeutics in a report on Tuesday, August 4th. They set a "buy" rating and a $55.00 target price on the stock. Finally, Citizens Jmp initiated coverage on shares of Sensei Biotherapeutics in a research note on Monday, July 20th. They issued an "outperform" rating and a $51.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $56.17.

Sensei Biotherapeutics Stock Performance

NASDAQ:FTH traded down $0.14 on Wednesday, hitting $19.51. The stock had a trading volume of 6,028 shares, compared to its average volume of 251,458. Sensei Biotherapeutics has a 52 week low of $7.45 and a 52 week high of $42.14. The company's fifty day moving average price is $28.24. The company has a market cap of $504.24 million, a P/E ratio of -0.14 and a beta of -0.15.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.13). As a group, analysts anticipate that Sensei Biotherapeutics will post -13.69 EPS for the current year.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of hedge funds have recently made changes to their positions in FTH. Candriam S.C.A. purchased a new stake in Sensei Biotherapeutics during the 3rd quarter valued at about $9,542,000. State of Wyoming bought a new stake in Sensei Biotherapeutics in the third quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Sensei Biotherapeutics by 48.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,360 shares of the company's stock valued at $150,000 after purchasing an additional 1,760 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Sensei Biotherapeutics during the second quarter valued at approximately $307,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics in the second quarter worth approximately $3,610,000. 10.50% of the stock is currently owned by institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company's research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei's pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company's ImmunoPhage platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.